

Supplementary Table 2. Disease control rates (DCR) recorded (partial response or stable disease) according to RECIST during first-line Molecular Targeted Therapy (MTT) in patients with PanNENs.

Patient Characteristics (n=57)		DCR in Everolimus group	DCR in Sunitinib group	P-value
		N=42	N=15	
Gender	Male	26/30	8/11	0.361
	Female	10/12	1/4	0.063
Age mean (SD)		56.2(13.8)	59.6(17.7)	0.543
Inheritance	Sporadic	32/38	8/13	0.333
	Familial (MEN1)	4/4	2/2	0.121
Liver Tumour Load	No liver metastases	2/2	1/2	-
	<5 unilobar liver metastases	8/9	1/1	0.999
	5-10 unilobar liver metastases and/or bilobar liver metastases	4/4	1/1	-
	>10 liver metastases or diffuse liver metastases	22/27	6/12	0.061
Ki67 Group	G1 (ki67 <3%)	5/7	2/2	0.999
	G2 (ki67 3-20%)	27/29	7/12	0.016
	G3 (ki67 >20%)	1/3	-	-
Secretory status	Yes	11/12	3/3	0.999
	No	25/30	6/12	0.026
Prior Surgery	Yes	18/19	6/10	0.036
	No	18/23	3/5	0.574
SRS or Ga68-PET	Positive	27/31	6/10	0.082
	Negative	4/4	3/3	-
	Unknown	5/7	0/2	-
FDG-PET	FDG-PET positive	1/3	1/3	0.999
	FDG-PET negative	8/8	2/3	0.273
	Unknown	27/31	6/9	-
Previous treatment	SSA or naive	28/30	3/6	0.024
	Pre-treated with chemotherapy	8/12	6/9	0.999
Charlson Comorbidity Index	0	27/31	7/11	0.174
	1	6/7	2/4	0.491
	2	3/4	-	-
	3	-	-	-

DCR: Disease Control Rate; MTT: Molecular Targeted Therapy; SD: Standard Deviation; SRS: somatostatin receptor scintigraphy; Ga: Gallium; FDG-PET: fluoro-deoxyglucose positron emission tomography

Pearson chi-square test and Fisher's exact test as well as student's t-test were conducted as appropriate.